if it is unclear whether the third party is living or deceased; or (c) the information is unrelated or irrelevant to the purpose of the disclosure.

The Board will take reasonable steps to ensure that individuals making public comment are aware of the fact that their comments (including their name, if provided) will appear in a transcript of the meeting posted on a public Web site. Such reasonable steps include: (a) A statement read at the start of each public comment period stating that transcripts will be posted and names of speakers will not be redacted; (b) A printed copy of the statement mentioned in (a) above will be displayed on the table where individuals sign up to make public comments; (c) A statement such as outlined in (a) above will also appear with the agenda for a Board Meeting when it is posted on the NIOSH Web site; (d) A statement such as in (a) above will appear in the Federal Register Notice that announces Board and Subcommittee meetings.

Contact Person For More Information: Theodore Katz, M.P.A., Designated Federal Officer, NIOSH, CDC, 1600 Clifton Road NE., MS E–20, Atlanta, GA 30333, Telephone: (513) 533–6800, Toll Free: 1–800–CDC– INFO, Email: dcas@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** Notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Gary J. Johnson,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2014–00042 Filed 1–7–14; 8:45 am] BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Request for Nominations of Candidates To Serve on the CDC/ HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment, Centers for Disease Control and Prevention, Health Resources and Services Administration

The Centers for Disease Control and Prevention (CDC) is soliciting nominations for possible membership on the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment (CHACHSPT).

The CHACHSPT provides advice to the Secretary, HHS; the Director, CDC; and the Administrator, Health Resources and Services Administration (HRSA), on objectives, strategies, policies, and priorities for HIV, Viral

Hepatitis, and STD prevention and treatment efforts including surveillance of HIV infection, AIDS, Viral Hepatitis, other STDs, and related behaviors; epidemiologic, behavioral, health services, and laboratory research on HIV/AIDS, Viral Hepatitis, and other STDs; identification of policy issues related to HIV/Viral Hepatitis/STD professional education, patient healthcare delivery, and prevention services; agency policies about prevention of HIV/AIDS, Viral Hepatitis and other STDs, treatment, healthcare delivery, and research and training; strategic issues influencing the ability of CDC and HRSA to fulfill their missions of providing prevention and treatment services; programmatic efforts to prevent and treat HIV, Viral Hepatitis, and other STDs; and support to the agencies in their development of responses to emerging health needs related to HIV, Viral Hepatitis and other STDs.

The CHACHSPT consists of 18 experts knowledgeable in the fields of public health, epidemiology, laboratory practices, immunology, infectious diseases, drug abuse, behavioral science, health education, healthcare delivery, state health programs, clinical care, preventive health, medical education, health services and clinical research, and healthcare financing, who are selected by the Secretary of the U.S. Department of Health and Human Services (HHS).

Nominations are being sought for individuals who have expertise and qualifications necessary to contribute to the accomplishments of the Committee's objectives.

Nominees will be selected from experts having experience in HIV/AIDS, Viral Hepatitis and STD prevention, control and treatment. Experts in the disciplines of epidemiology, laboratory practice, immunology, infectious diseases, drug abuse, behavioral science, health education, healthcare delivery, state health programs, clinical care, preventive health, medical education, health services and clinical research, healthcare financing and other related disciplines will be considered. The committee shall have at least four members who shall be persons living with HIV/AIDS.

Members may be invited to serve for terms of up to four years. The HHS policy stipulates that committee membership be balanced in terms of professional training and background, points of view represented and the committee's function. Consideration is given to a broad representation of geographic areas within the U.S., with equitable representation of the sexes, ethnic and racial minorities, and persons with disabilities. Nominees must be U.S. citizens, and cannot be full-time employees of the U.S. Government.

Candidates should submit the following items:

• Current *curriculum vitae,* including complete contact information (telephone numbers, mailing address, email address)

• A letter of recommendation from person(s) not employed by the U.S. Department of Health and Human Services

• A statement indicating the nominee's willingness to serve as a potential member of the Committee.

Nominations should be submitted electronically to *zkr7@cdc.gov* or in writing, to: Margie Scott-Cseh, Committee Management Specialist, NCHHSTP, CDC, 1600 Clifton Road NE., Mailstop: E07, Atlanta, GA 30333. All nominations must be postmarked by April 30, 2014.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention, and the Agency for Toxic Substances and Disease Registry.

Gary J. Johnson

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2014–00045 Filed 1–7–14; 8:45 am] BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Request for Nominations of Candidates To Serve on the Advisory Council for the Elimination of Tuberculosis, Centers for Disease Control and Prevention, Department of Health and Human Services

The Centers for Disease Control and Prevention (CDC) is soliciting nominations for possible membership on the Advisory Council for the Elimination of Tuberculosis (ACET).

ACET provides advice and recommendations to the Secretary, Department of Health and Human Services (HHS); the Assistant Secretary of Health; and the Director, CDC, regarding program policies, strategies, objectives, and priorities; address the development and application of new technologies; provide guidance and review on CDC's Tuberculosis Prevention Research portfolio and program priorities; and review the extent to which progress has been made toward eliminating tuberculosis.

ACET consists of 10 experts knowledgeable in the fields of public Health, epidemiology, immunology, infectious diseases, pulmonary disease, pediatrics, tuberculosis, microbiology, or preventive health care delivery, who are selected by the Secretary of the United State Department of Health and Human Services.

Nominations are being sought for individuals who have expertise and qualifications necessary to contribute to the accomplishments of the Council's objectives.

Nominees will be selected from experts having experience in tuberculosis prevention and control.

Experts in the disciplines of epidemiology, immunology, infectious diseases, pulmonary disease, pediatrics, tuberculosis, microbiology, preventive health care delivery, and experts in public health and other related disciplines will be considered. Members may be invited to serve up to four-year terms. The HHS policy stipulates that committee membership be balanced in terms of professional training and background, points of view represented and the council's function. Consideration is given to a broad representation of geographic areas within the U.S., with equitable representation of the sexes, ethnic and racial minorities, and persons with disabilities. Nominees must be U.S. citizens, and cannot be full-time employees of the U.S. Government.

Candidates should submit the following items:

• Current curriculum vitae, including complete contact information (telephone numbers, mailing address, email address)

• A letter of recommendation from person(s) not employed by the U.S. Department of Health and Human Services

• A statement indicating the nominee's willingness to serve as a potential member of the Council.

[^] Nominations should be submitted electronically or in writing, and must be postmarked by September 30, 2014, to: Margie Scott-Cseh, Committee Management Specialist, NCHHSTP, CDC, 1600 Clifton Road NE., Mailstop: E07, Atlanta, GA 30333, Email address: *zkr7@cdc.gov.*

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention, and the Agency for Toxic Substances and Disease Registry.

Gary J. Johnson,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2014–00044 Filed 1–7–14; 8:45 am] BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Community Living

Agency Information Collection Activities; Submission for OMB Review; Comment Request; Extension of Current Funding Opportunity Announcement and Grant Application Template for ACL Discretionary Grant Programs

AGENCY: Administration for Community Living, HHS.

ACTION: Notice.

SUMMARY: The Administration for Community Living (ACL) is announcing that the proposed collection of information listed below has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

DATES: Submit written comments on the collection of information by February 7, 2014.

ADDRESSES: Submit written comments on the collection of information by fax 202.395.6974 or by mail to the Office of Information and Regulatory Affairs, OMB, New Executive Office Bldg., 725 17th St. NW., Rm. 10235, Washington, DC 20503, Attn: Carolyn Lovett, Desk Officer for ACL.

FOR FURTHER INFORMATION CONTACT: Lori Stalbaum, (202) 357–3452 or *lori.stalbam@acl.hhs.gov*.

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, ACL has submitted the following proposed collection of information to OMB for review and clearance.

ACL is requesting an extension of the currently approved Administration on Aging (AoA) Funding Opportunity Announcement and Application Instructions Template for use for all ACL Discretionary Grant Programs, of which AoA is now a program center. This template provides the requirements and instructions for the submission of an application for discretionary grants funding opportunities. The template may be found on the ACL Web site at www.acl.gov/Funding_Opportunities/ Announcements/docs/ACL_PA_ Template_FINAL_8-12-13.doc. ACL estimates the burden of this collection of information as follows:

Frequency: 15—20 Funding Opportunity Announcements published annually.

Respondents: State agencies, public agencies, private non-profit agencies, institutions of higher education, and organizations including tribal organizations.

Estimated Number of Responses: 350 annually.

Total Estimated Burden Hours: 16,800.

Dated: January 2, 2014.

Kathy Greenlee,

Administrator and Assistant Secretary for Aging.

[FR Doc. 2014–00059 Filed 1–7–14; 8:45 am] BILLING CODE 4154–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2014-N-0001]

Nonprescription Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Nonprescription Drugs Advisory Committee.

General Function of the Committee: To provide advice and

recommendations to the Agency on FDA's regulatory issues.

Date and Time: The meeting will be held on February 26, 2014, from 8 a.m. to 12:30 p.m.

Location: FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993– 0002. Information regarding special accommodations due to a disability, visitor parking, and transportation may be accessed at: http://www.fda.gov/ AdvisoryCommittees/default.htm; under the heading "Resources for You," click on "Public Meetings at the FDA White Oak Campus." Please note that visitors to the White Oak Campus must enter through Building 1.

Contact Person: Glendolynn S. Johnson, Center for Drug Evaluation and